Pharm- Antimicrobials 10/05 Flashcards
Ampicillin, Drug Class
Penicillin; Aminopenicillin
Ampicillin, Spectrum
extended-spectrum; extends beyond gram-positive to gram-negative (Haemophilus influenzae, Escherichia coli, Proteus mirabilis), Listeria monocytogenes, susceptible meningococci, enterococci
“HEELP”
Ampicillin, MOA
Beta-lactam. structural analogs of D-Ala-D-Ala; Inhibits transpeptidation; covalently binds penicillin binding proteins (PBPs) preventing cross-linking of peptidoglycan; leads to cell autolysis
Ampicillin, ADR
Nausea, vomiting, diarrhea
Allergic reactions (0.7-10%)
Anaphylaxis (0.004-0.04%)
Pseudomembranous colitis
Amoxicillin, Drug Class
Penicillin; Aminopenicillin
Amoxicillin, Spectrum
extended-spectrum; extends beyond gram-positive to gram-negative (Haemophilus influenzae, Escherichia coli, Proteus mirabilis), Listeria monocytogenes, susceptible meningococci, enterococci
“HEELP”
Amoxicillin, MOA
Beta-lactam. structural analogs of D-Ala-D-Ala; Inhibits transpeptidation; covalently binds penicillin binding proteins (PBPs) preventing cross-linking of peptidoglycan; leads to cell autolysis
Amoxicillin, ADR
Nausea, vomiting, diarrhea
Allergic reactions (0.7-10%)
Anaphylaxis (0.004-0.04%)
Pseudomembranous colitis
Ceftriaxone, Drug Class
3rd generation cephalosporin, b-lactam
Ceftriaxone, Spectrum
less active against gram-positive, more active against Enterobacteriaceae (although resistance increasing due to B-lactamase producing strains)
“KEPSH”, don’t “tri” anything crazy –> gonorrhea
Ceftriaxone, MOA
Same as penicillins. Beta-lactam. structural analogs of D-Ala-D-Ala; Inhibits transpeptidation; covalently binds penicillin binding proteins (PBPs) preventing cross-linking of peptidoglycan; leads to cell autolysis
Ceftriaxone, ADR
Risk of cross reactivity with penicillins (1%)
Diarrhea
Ceftazidime, Drug Class
3rd generation cephalosporin, b-lactam
Ceftazidime, Spectrum
less active against gram-positive, more active against Enterobacteriaceae (although resistance increasing due to B-lactamase producing strains)
“KEPSH”
Ceftazidime, MOA
Same as penicillins. Beta-lactam. structural analogs of D-Ala-D-Ala; Inhibits transpeptidation; covalently binds penicillin binding proteins (PBPs) preventing cross-linking of peptidoglycan; leads to cell autolysis
Ceftazidime, ADR
Risk of cross reactivity with penicillins (1%)
Diarrhea
Cefepime, Drug Class
4th generation cephalosporin, penicillin
Cefepime, Spectrum
Extends beyond 3rd generation, useful in serious infections in hospitalized patients. Effective against Pseudomonas.
Cefepime, MOA
Same as penicillins. Beta-lactam. structural analogs of D-Ala-D-Ala; Inhibits transpeptidation; covalently binds penicillin binding proteins (PBPs) preventing cross-linking of peptidoglycan; leads to cell autolysis
Cefepime, ADR
Risk of cross reactivity with penicillins (1%)
Diarrhea
Meropenem, Drug Class
Carbapenem, b-lactam
Meropenem, Spectrum
Aerobes and anaeorbes; gram-positive, Enterobacteriaceae, Pseudomonas, Acinetobacter. Stenotrophomonas maltophilia is resistant.
“meroPEAnem” = pseudomonas, enterobacteriaceae, acinetobacter
Meropenem, MOA
Same as penicillins. Beta-lactam. structural analogs of D-Ala-D-Ala; Inhibits transpeptidation; covalently binds penicillin binding proteins (PBPs) preventing cross-linking of peptidoglycan; leads to cell autolysis
Meropenem, ADR
Nausea/vomiting (1-20%)
Seizures (1.5%)
Hypersensitivity
Ertapenem, Drug Class
Carbapenem, b-lactam
Ertapenem, Spectrum
Aerobes and anaeorbes; gram-positive, Enterobacteriaceae, Pseudomonas, Acinetobacter. Stenotrophomonas maltophilia is resistant.
“meroPEAnem” = pseudomonas, enterobacteriaceae, acinetobacter
Ertapenem, MOA
Same as penicillins. Beta-lactam. structural analogs of D-Ala-D-Ala; Inhibits transpeptidation; covalently binds penicillin binding proteins (PBPs) preventing cross-linking of peptidoglycan; leads to cell autolysis
Ertapenem, ADR
Nausea/vomiting (1-20%)
Seizures (1.5%)
Hypersensitivity
B-lactamase inhibitor prototypes
Ampicillin-sulbactam
Amoxicillin-clavulanic acid
Piperacillin-tazobactam
Ampicillin-sulbactam, Drug Class
B-lactamase inhibitor
Ampicillin-sulbactam, MOA
prevent destruction of B-lactam antibiotics
Amoxicillin-clavulanic acid, Drug Class
B-lactamase inhibitor
Aminopenicillin prototypes
Ampicillin
Amoxicillin
Cephalosporin prototypes
Cefriaxone, Ceftazidime
Cefepime
Carbapenem prototoypes
Meropenem
Ertapenem
Glycopeptide prototype
Vancomycin
Vancomycin, Drug Class
Glycopeptide
Vancomycin, Spectrum
Broad gram-positive coverage [S. aureus (including MRSA), S. epidermidis (including MRSE), Streptococci, Bacillus, Corynebacterium spp, Actinomyces, Clostridium]
ABCcDerm’SS = Actinomyces, Bacillus, Clostridium, Corynebacterium, S. epidermidis, S. aureus & Streptococci
Vancomycin, MOA
Inhibits cell wall synthesis; binds to D-alanyl-D-alanine of cell wall precursor units
Vancomycin, ADR
Macular skin rash, chills, fever, rash
Red-man syndrome (histamine release): extreme flushing, tachycardia, hypotension
Ototoxicity
Nephrotoxicity
Respiratory Fluoroquinolone prototoype
Levofloxacin
Levofloxacin, Drug Class
Fluoroquinolone (respiratory)
Levofloxacin, Spectrum
E. coli, Salmonella, Shigella, Enterobacter, Campylobacter, Neisseria, Pseudomonas aeruginosa, S. aureus (not MRSA), limited coverage of Streptococcus spp
Levofloxacin, MOA
Concentration-dependent; Targets bacterial DNA gyrase & topoisomerase IV
“FLOOR IT” = concentration dependent, give it everything you’ve got!
Levofloxacin, ADR
GI (3-17%): mild nausea, vomiting, abdominal discomfort
CNS (0.9-11%): mild headache, dizziness, delirium, rare hallucinations
Rash
Photosensitivity
Achilles tendon rupture
Contraindicated: children
“FluoroquinoLONES –> be good to your BONES”
Aminoglycoside, prototype
Gentamicin
Gentamicin, Drug Class
Aminoglycoside
Gentamicin, Spectrum
Aerobic gram-negative bacteria, limited action against gram-positive, synergistic bactericidal effects in gram-positive with cell wall active agent
Gentamicin, MOA
Concentration-dependent; Binds 30S ribosomal subunit; interferes with initiation of protein synthesis; causes misreading of mRNA
Gentamicin, ADR
Ototoxicity (up to 25%)
Nephrotoxicity (8-26%)
Neuromuscular block and apnea
Tetracycline prototype
Doxycycline
Doxycycline, Drug Class
Tetracycline
Doxycycline, Spectrum
Bacteriostatic; wide range of aerobic & anaerobic gram-positive and gram-negative activity; Rickettsia, Coxiella burnetii, Mycoplasma pneumoniae, Chlamydia spp, Legionella, atypical mycobacterium, Plasmodium, Borrelia burgdorferi (Lyme’s disease), Treponema pallidum (syphilis)
“My dachshund’s name is BART”: doxy = Borrelia, Atypicals (Mycoplasma, Legionella, Chlamydia), Rickettsia, Treponema
Doxycycline, MOA
Binds 30S ribosomal subunit; prevents access of aminoacyl tRNA to acceptor (A) site on mRNA ribosome complex
Doxycycline, ADR
GI (epigastric burning, N/V/D) C. difficile superinfections Photosensitivity Teeth discoloration Thrombophlebitis Contraindicated: children
Macrolide prototype
Azithromycin
Azithromycin, Drug Class
Macrolide
Azithromycin, Spectrum
Bacteriostatic; respiratory tract infections (spectrum S. pneumoniae, H. influenzae, and atypicals: Mycoplasma, Chalmydophilia, Legionella), alternative for otitis media , sinusitis, bronchitis, and SSTIs. Pertussis, gastroenteritis, H. pylori, Mycobacterial infections
“SHHAMP” = Strep, Haemophilus, Helicobacter, Atypicals, Mycobacterial, Pertussis
Azithromycin, MOA
Binds reversibly 50S ribosomal subunit; inhibits translocation
Azithromycin, ADR
GI: epigastric distress Hepatotoxicity Arrhythmia QT prolongation DDI: CYP3A4 inhibition - prolongs effects of digoxin, warfarin…
Lincosamide prototype
Clindamycin
Clindamycin, Drug Class
Lincosamide
Clindamycin, Spectrum
Bacteriostatic/-cidal (depends on conc, infection site, organism); Strep pneumoniae, pyogenes, viridans MSSA; anaerobes (B. fragilis)
Clindamycin, MOA
Binds 50S ribosomal subunit; inhibits translocation and suppresses protein synthesis
Clindamycin, ADR
GI: diarrhea (2-20%) Pseudomembranous colitis (0.01-10%) d/t C. difficile Skin rash (10%) Reversible increase in aminotransferase activity May potentiate neuromuscular blockade
50S ribosomal subunit inhibitors
Macrolides (Azithromycin)
Lincosamides (Clindamycin)
Linezolid
“buy AT 30, CEL at 50”
30S ribosomal subunit inhibitors
Aminoglycosides (Gentamicin)
Tetracyclines (Doxycycline)
“buy AT 30, CEL at 50”
Oxazolidinone prototype
Linezolid
Linezolid, Drug Class
Oxazolidinone
Linezolid, Spectrum
Gram-positive Staphylococcus (MSSA, MRSA, VRSA), Streptococcus (penicillin resistant S. pneumoniae), enterococci (VRE), gram-positive anaerobic cocci, gram-positive rods (Corynebacterium, L. monocytogenes)
Linezolid, ADR
Myelosuppression [thrombocytopenia (2.4%), anemia, leukopenia]
Headache
Rash
DDI: weak, nonspecific inhibitor of monoamine oxidase (antidepressants)
Linezolid, MOA
Inhibits protein synthesis binding P site of 50S ribosomal subunit, prevents formation of initiation complexes
Causes QT prolongation
Macrolides (Azithromycin)
Achilles Tendon Rupture
Fluoroquinolones (Levofloxacin)
DDI: CYP3A4 inhibition
Macrolides (Azithromycin)
Ototoxicity
Aminoglycosides (Gentamicin)
Glycopeptides (Vancomycin)
Nephrotoxicity
Aminoglycosides (Gentamicin)
Glycopeptides (Vancomycin)
Red-mann Syndrome
Glycopeptides (Vancomycin)
B-lactams
Penicillins, Cephalosporins, Carbapenems
Causes seizures
Carbapenems
MRSA
Vancomycin, Linezolid
Pseudomonas
Ceftzidime, Cefepime, Meropenem, Ertapenem, Levofloxacin, B-lactamase inhibitors
Anaerobes
Meropenem, Ertapenem, B-lactamase inhibitors, Doxycycline, Clindamycin, Linezolid (gram + anaerobic cocci)
Anaerobic coverage
Meropenem, Ertapenem, Doxycycline, Clindamycin, Linezolid
Piperacillin, Spectrum
extends spectrum to Pseudomonas aeruginosa, Enterobacter, and Proteus spp.
CURB 65 Criteria
Confusion Uremia BUN > 20 Respiratory rate >30bpm Low BP, SBP <90, DBP = 60 Age >/=65 0-1 = outpatient 2 = admit 3+ = often require ICU care
CURB 65 Minor Criteria
Multilobar infiltrates WBC < 4000 PLT <100,000 Core temp < 36C Hypotension requiring agggressive fluid resuscitation
absolute indications for ICU admission
mechanical ventilation septic shock (+ vasopressors)
CAP- Infecting Organisms for Underlying Bronchopulmonary disease
H. influenzae
Moraxella catarrhalis
+S. aureus during influenza outbreak
CAP- Infecting Organisms with chronic oral steroid use, severe underlying bronchopulmonary disease, alcoholism, or frequent antibiotic use
enterobacteriaceae
pseudomonas
CAP- Infecting Organisms with classic aspiration pleuropulmonary syndrome in alcohol/drug overdose or in seizures with gingival disease or esophageal motility disorders
anaerobes
CAP- Common viruses
influenza
RSV
adenovirus
parainfluenza virus
DOC for Non-resistant S. pneumoniae
PCN
Amoxicillin
DOC for Resistant S. pneumoniae
Cefotaxime, ceftriaxone, levofloxacin, vancomycin, linezolid (based on susceptibility)
DOC for non-beta lactase producing H. influenzae
amoxicillin
DOC for beta lactase producing H. influenzae
2nd or 3rd generation cephalosporin, amoxicillin/clavulanate
DOC for Mycoplasma pneumoniae
Macrolide, tetracycline
DOC for Chlamydophila pneumoniae
Macrolide, tetracycline
DOC for Chlamydophila psittaci
doxycycline
DOC for Legionella spp
FQ, azithromycin, doxycycline
DOC for Enterobacteriaceae (Klebsiella, E coli, Proteus)
3rd or 4th generation cephalosporin, carbapenem (if ESBL producer)
DOC for Pseudomonas
antipseudomonal b-lactam w/ ciprofloxacin, levofloxacin, or aminoglycoside
DOC for anaerobe (bacteroides, fusobacterium, peptostreptococcus)
b-lactam/b-lactamase inhibitor, clindamycin
DOC for MSSA
anti-staphylococcal PCN (nafcillin)
DOC for MRSA
vancomycin or linezolid
DOC for influenza virus
Oseltamivir, zanamivir
DOC for Pneuomcystic jiroveci
trimethoprim/sulfamethoxazole
DOC for Bordatella pertussis
azithromycin, clarithromycin
DOC for coccidioides spp
itraconazole, fluconazole (but no tx necessary if normal host)
DOC for Histoplasmosis
itraconazole
DOC for Blastomycosis
itraconazole
Oseltamivir, Drug Class
neuraminidase inhibitor
Oseltamivir, MOA
analogs of sialic acid, interferes with release of progeny influenza virus from infected host cell
Oseltamivir, ADR
N/V, abdominal pain (5-10%), headache, fever, diarrhea, neuropsychiatric effects (approved for children >/= 1 year)
neuraminidase inhibitor prototype
Oseltamivir
Azole prototypes
fluconazole, voriconazole
Azole, MOA
inhibits fungal cytochrome P450, reducing production of ergosterol
Azoles, ADRs
minor GI upset, abnormalities in liver enzymes, DDIs!!! i.e. prophylactically decrease warfarin
Voriconazole ADRs
visual changes, photosensitivity
Amphotericin B, MOA
binds ergosterol, changes permeability of cell, forms pores in membrane
Isoniazid, MOA
inhibits synthesis of mycelia acids. Prodrug, activated by KatG. Active form binds AcpM and KasA –> inhibits mycolic acid synthesis
Isoniazid, Resistance
mutation or deletion of katG gene
overexertion of inca and aphid
mutation in kasA
Isoniazid, ADRs
hepatotoxicity (minor elevation in LFTs 10-20%), clinical hepatitis (1%)
peripheral neuropathy
CNS toxicity (memory loss, psychosis, seizures)
Fever, skin rashes, drug-induced SLE
Rifampin, MOA
inhibits RNA synthesis (binds B-subunit of DNA-dependent RNA polymerase rpoB)
Rifampin, resistance
reduced binding affinity to RNA polymerase –> point mutations within rpoB gene
Rifampin, ADRs
Harmless red/orange color to secretions N/V (1.5%) rash fever hepatotoxicity flu-like syndrome (20%) in those tied <2x/week DDI: induces CYPs
Pyrazinamide, MOA
disrupts mycobacterial cell membrane synthesis and transport functions (exact mechanism unknown)
Pyrazinamide, Resistance
impaired biotransformation, mutation in pncA
Pyrazinamide, ADRs
hepatotoxicity (1-5%)!!
Gi upset
hyperuricemia (gouty arthritis)
Ethambutol, MOA
disrupts synthesis or arabinoglycan. inhibits mycobacterial arabinosyl transferase (encoded by embCAB operon)
Ethambutol, resistance
overexpression fo emb gene products
mutation in embB gene
Ethambutol, ADRs
retrobulbar neuritis (loss of visual acuity, red-green color blindness)
rash
drug fever
Streptomycin, Drug class=]
Aminoglycoside
Streptomycin, MOA
irreversible inhibitor of protein synthesis. binds S12 ribosomal protein of 30S subunit
Streptomycin, resistance
mutations in rpsL or rrs gene which alter binding site
Streptomycin, ADRs
ototoxicity (vertigo and hearing loss)
nephrotoxicity
relatively C/I in pregnancy (newborn deafness)
Latent TB infection treatment options
Isoniazid x9 mths QD or bi-weekly
Isoniazid & Rifapentine QW x12 by DOT (for pt’s 12+ y/o and HIV pt’s not on ART)
Rifampin QD x4 mths (pt’s intolerant or resistant to INH) or x6 mths in peds
Active TB initial therapy
x2 months INH rifampin pyrazinamide ethambutol